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Abstract The recent recognition that humans possess active
depots of brown adipose tissue has boosted the interest in this
tissue as a potential target for the prevention and treatment of
obesity and related metabolic disorders. Furthermore, it was
also revealed that brown adipose tissue (BAT) in humans may
consist of so-called beige or brite adipocytes. So far, cold
exposure is recognised as the strongest activator of BAT in
humans, but there is much ongoing research focused on find-
ing alternative activators of BAT. The consequences of long-
term BATactivation and/or cold exposure on metabolic health
are still unknown, and this represents an area of intensive
research. This is one of a series of commentaries under the
banner ‘50 years forward’, giving personal opinions on future
perspectives in diabetes, to celebrate the 50th anniversary of
Diabetologia (1965–2015).
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It was over 400 years ago that Conrad Gesner wrote about a fat
depot in the neck of marmots that could be called neither fat
nor flesh, but something in between [1]. More than 50 years
ago, Smith [2] first recognised the thermogenic capacity of
brown adipose tissue (BAT). This observation was followed
in 1978 by the identification of uncoupling protein-1 (UCP1)
as the principal component of brown adipose mitochondria
responsible for regulating energy dissipation [3]. Subsequently,
BAT was found to play an important role in the regulation of
cold- and diet-induced thermogenesis, and revealed to be
involved in body weight regulation in rodents [4]. In 2009,
following retrospective patient studies, dedicated cold expo-
sure studies using positron emission tomography–computed
tomography (PET/CT) imaging revealed functional ‘BAT’ in
humans, and confirmed the presence of increased levels of
UCP1 in this tissue, resulting in the general acceptance that
humans also possess active BAT stores [5–8]. In contrast to
rodents, the ‘BAT’ depot in humans may consist of both clas-
sical brown adipocytes and brown-like adipocytes dispersed in
white adipose tissue, but will be referred to as human BAT in
the remainder of this commentary.
The last 50 years have been characterised by a dramatic rise
in the prevalence of obesity and type 2 diabetes. Research
initially focused on the regulation of energy expenditure as a
crucial factor in the development of obesity, and it was indeed
recognised that a relatively low resting or 24 h energy expen-
diture predisposes individuals to the development of obesity
[9]. Mitochondrial energy dissipation via uncoupling was
therefore considered a target for obesity treatment. However,
the serious side effects of the uncontrolled use of the chemical
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uncoupler dinitrophenol (DNP), including hyperthermia and
even death, in the 1930s indicated that mitochondrial
uncoupling should be induced in a very regulated and con-
trolled manner, which diminished enthusiasm for mitochon-
drial uncoupling as a target for pharmacological intervention
at that time. Although studies in the late 1990s revealed that
UCP1 toxigene-mediated ablations of BAT resulted in the
development of obesity and diabetes at ambient temperatures
[4], the definitive identification of BAT in adult humans in
2009 really boosted hopes that enhancing energy expenditure
may be a realistic option for the prevention and treatment of
obesity-associated metabolic disorders. Indeed, studies con-
ducted in the last 5 years have hinted towards novel ways of
activating human BAT and have revealed that BAT activity
may indeed be related to energy expenditure (for review,
see [10]).
Energy turnover as a tool to combat obesity-related
metabolic disorders?
So can human BAT contribute to a solution to the metabolic
health problems that we are currently facing? Although the
idea that activating BATwill be the complete answer to a large
societal problem of habitual overeating and physical inactivity
is certainly oversimplifying things, there are positive reasons
to hope that the next 50 years will reveal major breakthroughs
in our understanding of how stimulating (brown) adipose tissue
and energy turnover may promote metabolic health.
First of all, the concept of energy balance as the most im-
portant factor in determining metabolic health will have to be
revisited. Instead, a high rate of energy and substrate turnover
may be crucial. Indeed, exercise and physical activity do not
usually result in negative energy balance or weight loss but are
important for maintaining metabolic health. Also, at the cellu-
lar level, the turnover of chemical energy and substrate seems
to determine cellular function. For example, the development
of insulin resistance and type 2 diabetes has been blamed, at
least in part, on ectopic fat accumulation in muscle, liver and
heart: consistent with the ‘energy balance’ concept, a low
mitochondrial oxidative capacity has subsequently been pro-
posed to underlie the fat accumulation in these tissues [11].
However, more recent findings suggest that a high—or stim-
ulated—mitochondrial function does prevent cellular
lipotoxicity, but not by lowering ectopic fat accumulation
[12]. To date, the exact mechanisms underlying these effects
are not understood, but the data suggest that the continuous
storage and breakdown of energy stores can prevent the neg-
ative consequences of excess energy storage. Over the next
50 years, we will learn if and how the dissipation of energy in
any given tissue can increase whole body energy fluxes and
may thereby promote cellular function and metabolic health.
Among the things we need to determine is how increasing
energy flux in one tissue can lead to effects in other tis-
sues—a field that is still in its infancy and was only initiated
some 20 years ago with the discovery that adipose tissue also
has an endocrine function and a role in inter-organ communi-
cation. The list of inter-organ signals secreted by white, brown
and beige adipocytes, muscle, liver and other tissues will
continue to increase in the coming years, and important
knowledge on the complex system of inter-organ communi-
cation will aid the development of targets for tissue-specific
manipulation of energy turnover.
The novel functions of fat, fat and fat
The discovery of human BATwill fuel a new line of research
dedicated to understanding the precise physiological function
of this tissue. For this, we first need a better understanding of
the anatomical locations of BAT in humans. In rodents, beige
fat is dispersed, and with the current techniques used to detect
BAT in humans we may only see tight depots and underesti-
mate its full potential. We also need to reveal whether BAT
‘only’ plays a role in thermoregulation or if this tissue has
other, yet unrevealed, functions. BAT activation requires fatty
acids and glucose as a fuel, and experimental evidence in
rodents suggests that BAT may be involved in the clearance
of glucose and triacylglycerols from the circulation. It is un-
known whether this is just a side effect of the (thermogenic)
activity of BAT or a dedicated and controlled function of this
tissue, nor is it known whether activation of BAT in humans
indeed can contribute to the regulation of circulating glucose
and triacylglycerol levels and thereby exert cardioprotective
and anti-diabetic effects, but data from animal studies are
promising [13, 14]. In fact, we are currently still facing exper-
imental limitations in detecting active BAT in humans, and the
gold standard so far—cold-induced glucose uptake using
2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG-PET/CT)—may
only reveal part of the activity of human BAT, and novel,
non-invasive techniques are warranted to study the metabo-
lism of BAT in humans in vivo in more detail.
Perhaps an even more promising ‘side effect’ of the current
renewed interest in the study of BAT is the recognition that not
all fat is the same.Whereas approximately 20 years ago, white
adipose tissue was considered a boring tissue serving mainly
as a large energy reservoir, the discovery of several adipokines
in the 1990s added a new dimension to the tissue as one of
endocrine origin. However, even nowadays, most people, in-
cluding health scientists and medical doctors, consider white
adipose tissue to be one single, albeit very large, organ, per-
haps with visceral adipose tissue considered as a special kind
of metabolically active fat. It is realistic to expect that the next
50 years will reveal that this is far from the truth. The study of
BAT has already revealed a new distinct type of thermogenic
fat cells located inwhite adipose tissue depots, termed beige or
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brite adipocytes, and their function has only just started to be
unravelled (Fig. 1). In fact, data now suggest that a major
portion of BAT in humans is not composed of classical brown
fat cells, as in the interscapular depots of rodents, but are
composed of beige cells [15]. It is clear that beige fat contrib-
utes to the metabolic health of genetically defined mouse
models [16], but how human beige fat cells contribute to en-
ergy metabolism needs further study. Also, we need to estab-
lish the specific and distinct physiological functions of brown
vs beige adipocytes.With the rapidly increasing developments
in molecular biology, new tools will become available that are
likely to result in the discovery of even more adipose tissue
cell types or subtypes and their associated functions. These all
providing new challenges to understanding the complex
system of metabolism, but also presenting new opportunities
for the development of finely tuned therapies for the treatment
of metabolic diseases.
Towards new therapies for diabetes and metabolic
complications of obesity
The discovery of new types of adipose cells, new adipokines
and new biological functions of tissues containing these cells
could provide many new potential therapies for the treatment
of obesity, diabetes and related disorders. The list of targets
that may induce browning or activate beige/brown adipose
tissue is expanding daily, and research in the coming years
will reveal which of these are robust enough to represent
new opportunities for human therapy. Several key questions
arise: first, is it more important to create new brown or beige
fat cells or to activate existing one in an individual, or do we
need to do both? Second, many studies in rodents have re-
vealed beneficial effects on glucose homeostasis and diabetes,
which may not be in proportions with effects on body weight
per se. Are there important effects of brown/beige fat that are
not strictly tied to effects on overall adiposity? It might be
foolish to place all our hope on novel pharmacological treat-
ment. It will remain very important that public health initia-
tives stress the health dangers of physical inactivity and over-
eating; the coming years will also reveal whether a lack of
time outside the thermoneutral zone should be considered an
additional danger to health. Based on the results to date, it can
be hypothesised that regular exposure to mild cold may be-
come—together with exercise and weight loss—a third life-
style factor that can be used to stimulate health [17]. As with
lifestyle and exercise, we need to understand how much cold
is enough; are we facing a ‘30 min of cold per day keeps the
doctor away’ advice, or will 30 min of cold per day not be
sufficient to counterbalance being in the thermoneutral zone
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Fig. 1 BAT contains high levels of UCP1, which allows it to perform its
major role of dissipating energy as heat. Cold acclimatisation and some
pharmacological agents have been shown to cause activation of BAT or
browning of white adipose tissue in adult humans, as indicated by the
darker areas on the [18F]FDG-PET/CT scans. As depicted in the illustra-
tion, the brown cells may originate from de novo recruitment of precursor
cells. The extent to which browning is accomplished by classical brown
adipocytes or the recruitment of beige cells in humans is still not
completely understood. Studies to date indicate that in humans the tissue
is heterogeneous with a mix of brown (beige) and white adipocytes, as
shown in the micrograph. As currently available techniques are not sen-
sitive enough to detect diffuse BAT, the precise anatomical location of
browning is worthy of more in-depth study. It is hoped that further de-
velopments in this field will reveal novel methods for the prevention and
treatment of obesity-associated metabolic disorders
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for 23.5 h per day, analogous to 30 min of exercise per day
perhaps not being sufficient to counterbalance 23.5 h of
sedentariness? The cold acclimatisation tests carried out to
date have lasted 2–6 h/day for 10 days to 6 weeks, with tem-
peratures varying from very cold (10°C with shivering) to
mild cold (19°C). Even mild cold (without shivering)
increases BAT activity, whole body energy metabolism and
decreases body fat, but long-term effects on measures of
health still need to be established, and optimal exposure times,
i.e. a compromise between realistic and effective, will need to
be figured out. Furthermore, it needs to be established whether
the potential beneficial effects of cold are only due to the
activation of BAT, or also involve other tissues with a thermo-
genic potential, such as skeletal muscle. Cooling protocols
would need to be developed taking into account the large
variability in individual and group-specific responses with
respect to effects on BATand energy metabolism and in terms
of acceptability, i. e. thermal comfort. These group-specific
responses also apply to potential side effects, as, for example,
the elderly may not respond adequately to prolonged mild
cold and their blood pressure may rise to unhealthy levels.
An interesting aspect of cold ‘therapy’ is that it can be
incorporated into our daily environment, i.e. the indoor envi-
ronment. Because most people are exposed to indoor condi-
tions for more than 90% of their time, health aspects of ambi-
ent temperatures warrant exploration. What would it mean if
we were to let our bodies, rather than the central heating,
control body temperature? Even if the effect at an individual
level is small, with widespread application in dwellings and
offices, the effect on the population could be significant. In the
built environment the temperature is controlled to satisfy ther-
mal comfort for the average (male) person. This is according
to the predicted mean vote model that is generally applied
worldwide. This results in relatively high temperatures in
wintertime. By lack of exposure to a varied ambient tempera-
ture, entire populations may be prone to developing diseases
such as obesity and in the same time may become more vul-
nerable to sudden temperature changes during cold waves.
Nowadays the so-called adaptive comfort model is more
widely applied. This model recognises that humans tolerate
and adapt to different thermal environmental conditions
depending on outdoor environmental conditions. For the next
50 years, we envision that indoor temperature will be used to
enhance metabolism and resilience, and thereby health in gen-
eral. Although scientific attention is now focused on cold, the
health aspects of mild heat are still an enigma and need to be
explored. Therefore the next 50 years will unravel whether,
from a health perspective, indoor temperatures should follow
outdoor temperature variation at acceptable but healthy levels,
both daily and seasonally.
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